Jung et al reported a prognostic score for a patient with myeloma who is classified as Stage II by the Revised International Staging System. This can help to better determine the outcome for the patient. The authors are from Chonnam National University, Sungkyunkwan University and Yonsei University in South Korea.
Patient selection: Korean patient with myeloma classified as Stage II by the revised ISS
Parameters:
(1) ECOG performance status
(2) del(17p)
(3) hypodiploidy
(4) platelet count in 10^9/L
Parameter
Finding
Points
ECOG performance status
0 or 1
0
2 to 4
1
del(17p)
absent
0
present
1
hypodiploidy
no
0
yes
1
platelet count
> 140 *10^9/L
0
<= 140 * 10^9/L (thrombocytopenia)
1
total score =
= SUM(points for all 4 parameters)
Interpretation:
• minimum score: 0
• maximum score: 4
• The higher the score the worse the cumulative survival.
Total Score
Risk Group
Median Overall Survival
0
low
62.9 months
1
intermediate
35.4 months
2 to 4
high
15.1 months
To read more or access our algorithms and calculators, please log in or register.
